Patents by Inventor Mark McCamish
Mark McCamish has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220185905Abstract: The invention provides multispecific agents having one arm binding CD47, and a second arm binding to CD24. The invention also provides multispecific agents having one arm binding to SIRP? and a second arm binding to siglec-10.Type: ApplicationFiled: March 25, 2020Publication date: June 16, 2022Inventors: Mark McCamish, Jens-Peter Volkmer
-
Publication number: 20160371427Abstract: Methods of treating an individual exhibiting a medical condition are disclosed. The methods involve determining a score of an individual based on the individual's genotypic information, comparing the score to at least one threshold value, wherein the result of the comparison is indicative of a beneficial response to a treatment, and providing a suitable treatment to the individual.Type: ApplicationFiled: May 20, 2016Publication date: December 22, 2016Inventors: David R. Cox, Mark A. McCamish
-
Publication number: 20140018258Abstract: Methods of treating an individual exhibiting a medical condition are disclosed. The methods involve determining a score of an individual based on the individual's genotypic information, comparing the score to at least one threshold value, wherein the result of the comparison is indicative of a beneficial response to a treatment, and providing a suitable treatment to the individual.Type: ApplicationFiled: September 18, 2013Publication date: January 16, 2014Applicant: Genetic Technologies Ltd.Inventors: David R. Cox, Mark A. McCamish
-
Publication number: 20130296178Abstract: Methods of treating an individual exhibiting a medical condition are disclosed. The methods involve determining a score of an individual based on the individual's genotypic information, comparing the score to at least one threshold value, wherein the result of the comparison is indicative of a beneficial response to a treatment, and providing a suitable treatment to the individual.Type: ApplicationFiled: January 24, 2013Publication date: November 7, 2013Inventors: David R. Cox, Mark A. McCamish
-
Publication number: 20110200588Abstract: Methods of treating an individual exhibiting a medical condition are disclosed. The methods involve determining a score of an individual based on the individual's genotypic information, comparing the score to at least one threshold value, wherein the result of the comparison is indicative of a beneficial response to a treatment, and providing a suitable treatment to the individual.Type: ApplicationFiled: April 27, 2011Publication date: August 18, 2011Applicant: Perlegen Sciences, Inc.Inventors: David R. Cox, Mark A. McCamish
-
Publication number: 20090087854Abstract: Methods of treating an individual exhibiting a medical condition are disclosed. The methods involve determining a score of an individual based on the individual's genotypic information, comparing the score to at least one threshold value, wherein the result of the comparison is indicative of a beneficial response to a treatment, and providing a suitable treatment to the individual.Type: ApplicationFiled: September 23, 2008Publication date: April 2, 2009Applicant: Perlegen Sciences, Inc.Inventors: David R. Cox, Mark A. McCamish
-
Publication number: 20080280955Abstract: In one aspect, the invention provides a method of screening and, optionally, treatment of an individual suffering from an insulin resistance disorder by screening an individual in need of treatment for an insulin resistance disorder for one or more genetic variations indicating a predisposition to a response to an insulin sensitizer; and, optionally, administering or not administering an insulin sensitizer to the individual based on the results of the screening. The insulin sensitizer for which the individual is screened and the insulin sensitizer that is administered or not administered may be the same or different. In another aspect, the invention provides methods comprising identifying one or more genetic variations, e.g.Type: ApplicationFiled: September 29, 2006Publication date: November 13, 2008Applicant: Perlegen Sciences, Inc.Inventor: Mark A. McCamish
-
Publication number: 20070196445Abstract: The present invention relates to methods and nutritional compositions for the prevention and treatment of cachexia and anorexia. The methods of the invention comprise administering a composition comprising effective amounts of ?-3 fatty acids such as alpha-linolenic acid, stearidonic acid, eicosapentaenoic acid, docosapentaenoic acid, docosahexaenoic acid or mixtures thereof; of branched-chain amino acids valine, leucine, isoleucine or mixtures thereof; with or without reduced levels of tryptophan and 5-hydroxytryptophan; and of antioxidant system selected from the group comprising beta-carotene, vitamin C, vitamin E, selenium, or mixtures thereof.Type: ApplicationFiled: April 16, 2007Publication date: August 23, 2007Inventors: Bonnie Abbruzzese, Mark McCamish, Frederick Cope, Stephen Demichele
-
Publication number: 20070037198Abstract: Methods are described for assessing an individual's likelihood of developing or exhibiting a multifactorial trait, and for predicting the effectiveness of a drug treatment regimen in an individual. The methods include determining a plurality of genotypes for the individual at a plurality of biallelic polymorphic loci, using the genotypes to compute a score for the individual, and comparing the score to at least one threshold value. Genetic tests are also described for assessing an individual's likelihood of developing or exhibiting a multifactorial trait.Type: ApplicationFiled: August 25, 2006Publication date: February 15, 2007Applicant: Perlegen Sciences, Inc.Inventors: David Cox, Mark McCamish
-
Patent number: 7127355Abstract: Several methods are described for assessing an individual's likelihood of developing or exhibiting a multifactorial trait. The methods include determining a plurality of genotypes for the individual at a plurality of biallelic polymorphic loci, using the genotypes to compute a score for the individual, and comparing the score to at least one threshold value.Type: GrantFiled: September 30, 2004Date of Patent: October 24, 2006Assignee: Perlegen Sciences, Inc.Inventors: David Cox, Mark McCamish
-
Publication number: 20060211684Abstract: The present invention provides a strategy to compensate for deficiency in the alpha-2C receptor by administering an agonist of different receptors; the alpha-2A and/or dopamine d2 receptors. These receptors are fully functional and receptive to stimulation by an agonist. Agonism of the alpha-2A and/or dopamine d2 receptors by clonidine, Nolomirole or other suitable agonist may down regulate epinephrine production, and hence compensate for the deficiency in the alpha-2C receptor. Such methods are useful for treating a variety of cardiovascular disorders.Type: ApplicationFiled: January 13, 2006Publication date: September 21, 2006Applicant: Perlegen Sciences, Inc.Inventor: Mark McCamish
-
Publication number: 20050196770Abstract: Several methods are described for assessing an individual's likelihood of developing or exhibiting a multifactorial trait. The methods include determining a plurality of genotypes for the individual at a plurality of biallelic polymorphic loci, using the genotypes to compute a score for the individual, and comparing the score to at least one threshold value.Type: ApplicationFiled: September 30, 2004Publication date: September 8, 2005Applicant: Perlegen Sciences, Inc.Inventors: David Cox, Mark McCamish
-
Publication number: 20050014785Abstract: The present invention provides methods and compositions for the treatment of DNA damage related disorders. One embodiment is a method for the inhibition of side effects associated with chemotherapeutic and radiotherapeutic agents using chloroquine compounds. Another embodiment is a method for treatment and/or prevention of lethal or sub-lethal radiation toxicities associated with terrorist acts or war.Type: ApplicationFiled: May 27, 2004Publication date: January 20, 2005Applicants: Perlegen Sciences, Inc., St. Jude Children's Research HospitalInventors: Michael Kastan, Christopher Bakkenist, Mark McCamish
-
Patent number: 5531734Abstract: A method is disclosed for modifying a liquid enteral nutritional product during delivery thereof from a supply container to a feeding tube delivering the nutritional product to the gastrointestinal tract of a patient. During enteral tube feeding the nutritional product passes through a formulation chamber, e.g., a drip chamber, having located therein at least one controlled release dosage form unit containing at least one beneficial agent. The beneficial agent may be selected from nutrients, medicaments, probiotics, or diagnostic agents or mixtures thereof, and any such together with a physiologically acceptable marker dye in controlled release dosage form and/or the same or different additional beneficial agent not in controlled release dosage form. Controlled release dosage forms may be of a conventional sustained release type or an osmotically driven delivery device.Type: GrantFiled: January 13, 1995Date of Patent: July 2, 1996Assignee: Abbott LaboratoriesInventors: Ronita K. Geckle, Terrence B. Mazer, Joseph E. Walton, Carl J. Piontek, Susan B. Duel, Andre Daab-Krzykowski, Mark A. McCamish, Robert L. Joseph, William G. Pierson
-
Patent number: 5531681Abstract: An apparatus is disclosed for modifying a liquid enteral nutritional product during delivery thereof from a supply thereof, such as a hangable container, to a feeding tube delivering the liquid enteral nutritional product to the gastrointestinal tract of a patient. The apparatus has at least one formulation chamber, such as a drip chamber, with at least one controlled release dosage form unit in the form of a coated tablet, osmotically driven device, coated capsule, microencapsulated microspheres, agglomerated molecular sieving type material, or a quantity of fine hollow permeable fibers located therein. The controlled release dosage form unit or units contain at least one beneficial agent selected from nutrients, medicaments, probiotics, or diagnostic agents or mixtures thereof, to any of which a physiologically acceptable marker dye in controlled release dosage form and/or the same or different beneficial agent not in controlled release dosage form may be added.Type: GrantFiled: January 13, 1995Date of Patent: July 2, 1996Assignee: Abbott LaboratoriesInventors: Joseph E. Walton, Terrence B. Mazer, Ronita K. Geckle, Carl J. Piontek, Susan B. Duel, Andre Daab-Krzykowski, Mark A. McCamish, Robert L. Joseph, William G. Pierson
-
Patent number: 5508308Abstract: A therapeutic method is provided to reduce ischemia/reperfusion injury to the heart muscle by perfusing pyruvylglycine into the circulatory system of a patient who has had a heart attack or suffered coronary occlusion.Type: GrantFiled: January 31, 1995Date of Patent: April 16, 1996Assignee: Abbott LaboratoriesInventors: Robert H. Miller, Mark A. McCamish, Ronald T. Stanko
-
Patent number: 5318543Abstract: A laparoscopic jejunostomy instrumentation kit includes components for securing a patient's intestine in apposition to the patient's abdominal wall and for creating a stoma through the patient's abdominal wall and intestinal wall, a jejunostomy tube, and an enclosure for containing the other components of the kit. In preferred embodiments the kit includes T-Fastener assemblies, needles, syringes, a dilator, a peel-away sheath and a gastrostomy tube.Type: GrantFiled: October 8, 1992Date of Patent: June 7, 1994Assignee: Abbott LaboratoriesInventors: Jeffrey R. Ross, Mark A. McCamish, Andrea L. Senokozliff-Englehart, Roger G. Danis
-
Patent number: 5263490Abstract: An apparatus may be employed for determining the relaxation rate of a muscle which has been caused to contract in response to an electrical stimulus. The relaxation rate may be used in evaluating a person's nutritional status. The apparatus has support for supporting the forearm and wrist of a person in a palm-up position with the wrist extended. An electrical stimulus is applied to the person's ulnar nerve, and the force exerted upon a load cell by the person's thumb is measured. A computer is employed for receiving, storing, plotting and analyzing the force data collected by a transducer.Type: GrantFiled: July 27, 1992Date of Patent: November 23, 1993Assignee: Abbott LaboratoriesInventors: James P. Hayes, James L. Tiefenthal, Mark A. McCamish, Jeffrey R. Ross